CIO.Inc: Can AI Finally Close the Gap Between Science and Software?
Alister Campbell, VP at Dotmatics, explains in CIO.Inc how AI is addressing the longstanding "last mile" challenge of translating scientific models into scalable software applications, enabling faster, more cost-effective development of personalized medicines and potentially revolutionizing patient access to safer therapeutics.
In this CIO.Inc feature, Alister Campbell, vice president of global science and technology at Dotmatics, discusses how traditionally, science has moved faster than software, but artificial intelligence might be closing the gap.
The piece highlights that the historical challenge has been the "last mile" problem—transitioning a model from a data scientist's notebook to an integrated, scalable, and reliable application. This gap often caused delays, failures, and wasted resources.
Dotmatics is leading this race to AI—empowering scientists with tools that act like “a thousand lab researchers at their side.” The result: faster, more cost-effective development of life-saving therapeutics, and a future where patients gain access to safer, more personalized medicines in years instead of decades.
Watch the full interview to hear Dotmatics' perspective on how AI is reshaping the future of medicine.
Related
NBC News: How AI is Transforming Drug Discovery
In an NBC News segment, Alister Campbell, VP of Dotmatics, explains how the company leverages AI to analyze large datasets, predict effective drug compounds, and streamline fragmented data systems and manual workflows, thereby accelerating and improving the efficiency of drug discovery.
Addressing Inefficient R&D Workflows
The blog discusses how legacy, fragmented R&D systems hinder innovation in complex, multi-domain scientific research by creating silos and inefficiencies, and presents Dotmatics’ unifying platform as a comprehensive solution that integrates diverse tools, data, and teams to enable smarter collaboration, governed data use, and AI-driven automation for faster, more rigorous innovation.
Simplify your laboratory workflow management with Dotmatics
Dotmatics offers a unified scientific R&D platform that streamlines laboratory workflow management by integrating various scientific applications, automating data extraction, cleaning, and harmonization into FAIR formats, thereby reducing manual data handling, enhancing collaboration, and accelerating the R&D cycle to help life sciences organizations bring new therapies to market faster.
Dotmatics helping scientists make better drugs in less time using AI
Dotmatics executives Kalim Saliba and Steve Tharp explain in a CBS News Boston feature how the company leverages artificial intelligence to transform pharmaceutical drug discovery by providing innovative solutions that accelerate and improve the efficiency of scientific research and development in the life sciences sector.
The Future of AI in Drug Discovery
The Forbes article discusses how AI is revolutionizing drug discovery by accelerating R&D and improving decision-making, highlighting Dotmatics’ role in integrating data and applying AI to scientific workflows, while also connecting these advancements to broader innovations in sustainability and global problem-solving.
CBS News: How AI Is Accelerating Safer, More Personalized Drug Discovery
In a CBS News interview, Dotmatics VP Phil Mounteney explains how their internally developed AI models accelerate drug discovery by analyzing early-phase research data to shorten development cycles, reduce costs, and deliver safer, personalized therapies while maintaining data privacy.